Claims
- 1. A process for preparing a direct positive photosensitive material comprising providing on a support at least one silver halide light-sensitive emulsion layer comprising the combination of (a) non-prefogged internal latent image silver halide core/shell grains; (b) a binder; (c) at least one compound represented by Formula (I), (II) or (III); and at least one compound represented by formula (IV):
- R--SO.sub.2 S--M (I)
- R--SO.sub.2 S--R.sup.1 (II)
- R--SO.sub.2 S--L.sub.m --S.O.sub.2 S--R.sup.2 (III)
- wherein R, R.sup.1 and R.sup.2 each represents a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic group; M represents a cation; L represents a divalent linking group; and m is 0 or 1; and
- R.sup.3 --SO.sub.2 M.sup.1 (IV)
- wherein R.sup.3 represents a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group, or a substituted or unsubstituted heterocyclic group; and M.sup.1 represents a cation,
- wherein said silver halide light-sensitive emulsion layer comprises said compound represented by formula (I), (II) or (III) in an amount of from 10.sup.-5 to 10.sup.-2 mol per mol of said internal latent image silver halide,
- wherein said silver halide light-sensitive emulsion layer comprises said compound represented by formula (IV) in an amount of from 10.sup.-7 to 10.sup.-3 mol per mol of said internal latent image silver halide,
- by adding said at least one compound represented by formulae (I), (II) and (III) and said at least one compound represented by formula (IV) during formation of the silver halide core grains or during chemical sensitization of the silver halide core grains.
- 2. The process as claimed in claim 1, wherein said heterocyclic group represented by R, R.sup.1 and R.sup.2 is pyrrolidine, piperidine, pyridine, tetrahydrofuran, thiophene, oxazole, thiazole, imidazole, benzothiazole, benzoxazole, benzimidazole, selenezole, benzoselenazole, tellurazole, triazole, benzotriazole, tetrazole, oxadiazole or thiadiazole.
- 3. The process as claimed in claim 1, wherein each said substituted group R, R.sup.1 and R.sup.2 is substituted with a substituent selected from the group consisting of an alkyl group, an alkoxy group, an aryl group, a hydroxyl group, a halogen atom, an aryloxy group, an alkylthio group, an arylthio group, an acyl group, a sulfonyl group, an acylamino group, a sulfonylamino group, an acyloxy group, a carboxyl group, a cyano group, a sulfo group and an amino group.
- 4. The process as claimed in claim 1, wherein said divalent linking group represented by L is selected from --(CH.sub.2).sub.m --, --CH.sub.2 CH.dbd.CH--CH.sub.2 --, --CH.sub.2 C.tbd.CCH.sub.2 --, ##STR7## xylylene, phenylene and naphthylene, wherein m is an integer of 1 to 12.
- 5. The process as claimed in claim 1, wherein said silver halide light-sensitive emulsion layer comprises at least one compound represented by formula (I).
- 6. The process as claimed in claim 1, wherein said silver halide light-sensitive emulsion layer comprises said compound represented by formula (IV) in an amount of from 10.sup.-6 to 10.sup.-3 mol per mol of said internal latent image silver halide.
- 7. The process as claimed in claim 1, wherein said non-prefogged internal latent image silver halide comprises at most 3 mol % silver iodide.
- 8. The process as claimed in claim 7, wherein said non-prefogged internal latent image silver halide contains substantially no silver iodide.
- 9. The process as claimed in claim 9, wherein said non-prefogged internal latent image silver halide is a monodisperse emulsion having an average grain size of from 0.15 to 1 .mu.m.
- 10. The process as claimed in claim 1, wherein at least one layer of said material comprises a nucleating agent.
- 11. The process as claimed in claim 10, wherein said nucleating agent is present in said silver halide light-sensitive emulsion layer.
- 12. The process as claimed in claim 11, wherein said nucleating agent is represented by formula (N-I): ##STR8## wherein Z represents a non-metallic atomic group necessary for forming a substituted or unsubstituted 5-membered or 6-membered heterocyclic ring; R.sup.4 represents a substituted or unsubstituted aliphatic group; and R.sup.5 represents hydrogen, a substituted or unsubstituted aliphatic group or a substituted or unsubstituted aromatic group; provided that at least one of R.sup.4, R.sup.5 and Z comprises an alkenyl group, an acyl group, a hydrazine group or a hydrazone group; Y represents a counter ion required for charge balance; and n is 0 or 1.
- 13. The process as claimed in claim 12, wherein R.sup.4 and R.sup.5 are linked to form a dihydropyridinium group.
- 14. The process as claimed in claim 13, wherein at least one of R.sup.4, R.sup.5 and Z is substituted with a group capable of promoting adsorption to silver halide.
- 15. The process as claimed in claim 11, wherein said nucleating agent is represented by formula (N-II): ##STR9## wherein R.sup.21 represents a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aromatic group or a substituted or unsubstituted heterocyclic group; R.sup.22 represents hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted aryloxy group, or a substituted or unsubstituted amino group; G represents a carbonyl group, a sulfonyl group, a sulfoxy group, a phosphoryl group or an iminomethylene group; at least one of R.sup.23 and R.sup.24 represents hydrogen, and the other represents hydrogen, a substituted or unsubstituted alkylsulfonyl group, a substituted or unsubstituted arylsulfonyl group, or a substituted or unsubstituted acyl group; provided that G, R.sup.22 and R.sup.24 may be linked to form a hydrazone structure.
- 16. The process as claimed in claim 11, wherein said nucleating agent is present in an amount of from 10.sup.-8 to 10.sup.-2 mol per mol of said non-prefogged internal latent image silver halide.
- 17. The process as claimed in claim 16, wherein at least one layer of said material comprises a nucleation accelerator.
Priority Claims (1)
Number |
Date |
Country |
Kind |
63-221483 |
Sep 1988 |
JPX |
|
Parent Case Info
This is a divisional of application Ser. No. 07/403,509, filed Sept. 6, 1989, now abandoned.
US Referenced Citations (5)
Foreign Referenced Citations (3)
Number |
Date |
Country |
0249239 |
Jun 1987 |
EPX |
0293917 |
Dec 1988 |
EPX |
0327066 |
Feb 1989 |
EPX |
Non-Patent Literature Citations (2)
Entry |
Research Disclosure No. 235, Nov. 1983, Havant GB, pp. 346-352, "Development Nucleation by Hydrazine & Hydrazine Derivatives". |
European Search Report dated Apr. 12, 1990. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
403509 |
Sep 1989 |
|